Recombinant Newcastle disease virus expressing the infectious bronchitis virus S1 gene protects chickens against Newcastle disease virus and infectious bronchitis virus challenge

Zhao, Rongjun; Sun, Jiazhi; Qi, Tiancong; Zhao, Wen; Han, Zongxi; Xiao-pu, Yang; Liu, Shengwang

doi:10.1016/j.vaccine.2017.03.045

Cited by 36 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the scores in the groups treated with the recombinant IBVs and Beaudette differed significantly from those with ck/CH/ LDL/091022. Finally, no IBV RNA was detected in the oropharyngeal swabs from chickens inoculated with the recombinant IBVs and Beaudette after 4, 8, 12, 16, and 20 days by real-time RT-PCR, where the results were considered positive when the Ct value was less than 32 Zhao et al, 2017). The results confirmed that the recombinant IBVs were avirulent according to the histomorphometry and histopathology findings.…”

Section: Pathogenicity Of the Recombinant Ibvsmentioning

confidence: 57%

Effects of hypervariable regions in spike protein on pathogenicity, tropism, and serotypes of infectious bronchitis virus

et al. 2018

Self Cite

View full text Add to dashboard Cite

To study the roles of hypervariable regions (HVRs) in receptor-binding subunit S1 of the spike protein, we manipulated the genome of the IBV Beaudette strain using a reverse genetics system to construct seven recombinant strains by separately or simultaneously replacing the three HVRs of the Beaudette strain with the corresponding fragments from a QX-like nephropathogenic isolate ck/CH/LDL/091022 from China. We characterized the growth properties of these recombinant IBVs in Vero cells and embryonated eggs, and their pathogenicity, tropism, and serotypes in specific pathogen-free (SPF) chickens. All seven recombinant IBVs proliferated in Vero cells, but the heterogenous HVRs could reduce their capacity for adsorption during in vitro infection. The recombinant IBVs did not significantly increase the pathogenicity compared with the Beaudette strain in SPF chickens, and they still shared the same serotype as the Beaudette strain, but the antigenic relatedness values between the recombinant strain and Beaudette strain generally decreased with the increase in the number of the HVRs exchanged. The results of this study demonstrate the functions of HVRs and they may help to develop a vaccine candidate, as well as providing insights into the prevention and control of IBV.

show abstract

Section: Pathogenicity Of the Recombinant Ibvsmentioning

confidence: 57%

Effects of hypervariable regions in spike protein on pathogenicity, tropism, and serotypes of infectious bronchitis virus

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, since several studies have shown that most of the neutralizing epitopes against IBV are found in the S1 protein, recombinant viral vectors expressing the IBV S1 protein have the potential to induce protective immune responses in vaccinated chickens. Recently, recombinant NDV strain LaSota engineered to express LX4 type IBV S1 protein has been shown to induce strong cellular and humoral immunity, which provides complete protection against both virulent NDV and LX4 type IBV challenge [54]. Indeed, after vaccination with this bivalent vaccine and subsequent challenge with a virulent IBV field isolate, a marked reduction in the replication of the challenge virus in the trachea was observed especially after booster vaccination [54].…”

Section: Engineered Ndv As a Bivalent Vaccine In Poultrymentioning

confidence: 99%

“…Recently, recombinant NDV strain LaSota engineered to express LX4 type IBV S1 protein has been shown to induce strong cellular and humoral immunity, which provides complete protection against both virulent NDV and LX4 type IBV challenge [54]. Indeed, after vaccination with this bivalent vaccine and subsequent challenge with a virulent IBV field isolate, a marked reduction in the replication of the challenge virus in the trachea was observed especially after booster vaccination [54]. More recently, engineered NDV expressing IBV complete S, S1 or S2 proteins was shown to completely protect against both virulent NDV and IBV challenge, with the highest protective efficacy demonstrated by rNDV expressing complete IBV S protein [42].…”

Section: Engineered Ndv As a Bivalent Vaccine In Poultrymentioning

confidence: 99%

Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology

Bello

Yusoff

Ideris

et al. 2020

Viruses

View full text Add to dashboard Cite

Many traditional vaccines have proven to be incapable of controlling newly emerging infectious diseases. They have also achieved limited success in the fight against a variety of human cancers. Thus, innovative vaccine strategies are highly needed to overcome the global burden of these diseases. Advances in molecular biology and reverse genetics have completely restructured the concept of vaccinology, leading to the emergence of state-of-the-art technologies for vaccine design, development and delivery. Among these modern vaccine technologies are the recombinant viral vectored vaccines, which are known for their incredible specificity in antigen delivery as well as the induction of robust immune responses in the vaccinated hosts. Although a number of viruses have been used as vaccine vectors, genetically engineered Newcastle disease virus (NDV) possesses some useful attributes that make it a preferable candidate for vectoring vaccine antigens. Here, we review the molecular biology of NDV and discuss the reverse genetics approaches used to engineer the virus into an efficient vaccine vector. We then discuss the prospects of the engineered virus as an efficient vehicle of vaccines against cancer and several infectious diseases of man and animals.

show abstract

“…Spike protein subunits of different viruses have been used in vaccination studies with success. Newcastle disease virus, for instance, has been modified to express the S subunit and was found to provide protection comparable to commercial vaccines after two vaccinations ([ 45 ]. Similar observations have been found using baculovirus [ 46 ]and fowl adenovirus [ 47 ]vectors.…”

Section: Discussionmentioning

confidence: 99%

A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus

Helal

Karch

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

Infectious bronchitis virus (IBV) affects poultry respiratory, renal and reproductive systems. Currently the efficacy of available live attenuated or killed vaccines against IBV has been challenged. We designed a novel IBV vaccine alternative using a highly innovative platform called Self-Assembling Protein Nanoparticle (SAPN). In this vaccine, B cell epitopes derived from the second heptad repeat (HR2) region of IBV spike proteins were repetitively presented in its native trimeric conformation. In addition, flagellin was co-displayed in the SAPN to achieve a self-adjuvanted effect. Three groups of chickens were immunized at four weeks of age with the vaccine prototype, IBV-Flagellin-SAPN, a negative-control construct Flagellin-SAPN or a buffer control. The immunized chickens were challenged with 5x104.7 EID50 IBV M41 strain. High antibody responses were detected in chickens immunized with IBV-Flagellin-SAPN. In ex vivo proliferation tests, peripheral mononuclear cells (PBMCs) derived from IBV-Flagellin-SAPN immunized chickens had a significantly higher stimulation index than that of PBMCs from chickens receiving Flagellin-SAPN. Chickens immunized with IBV-Flagellin-SAPN had a significant reduction of tracheal virus shedding and lesser tracheal lesion scores than did negative control chickens. The data demonstrated that the IBV-Flagellin-SAPN holds promise as a vaccine for IBV.

show abstract

Recombinant Newcastle disease virus expressing the infectious bronchitis virus S1 gene protects chickens against Newcastle disease virus and infectious bronchitis virus challenge

Cited by 36 publications

References 45 publications

Effects of hypervariable regions in spike protein on pathogenicity, tropism, and serotypes of infectious bronchitis virus

Effects of hypervariable regions in spike protein on pathogenicity, tropism, and serotypes of infectious bronchitis virus

Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology

A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus

Contact Info

Product

Resources

About